spacer
home > ict > spring 2017 > reaching out
PUBLICATIONS
International Clinical Trials

Reaching Out

To meet future demand for patients willing to enrol in dermatology clinical trials, sponsors will need to continue to advance and improve on the recruitment methods emerging today. Dermatological studies are increasing in number and, from January 2013 to January 2016, the number of dermatological pipeline projects rose by 43% (see Table 1) (1,2).

Perhaps even more telling is that two dermatologic conditions – acne and atopic dermatitis – are among the top five medical conditions by the number of trials actively enlisting volunteers across all indications (see Table 2, page 22) (3). With this strong demand for dermatology study participants, sponsors will require effective strategies to successfully meet enrolment targets. Online recruiting methods, for example, are now gaining traction. They show positive signals towards return on investment and are, therefore, starting to become more mainstream. In turn, cultural mores will impact how new approaches are accepted and thus must be taken into account as they are applied to the global market. Only by understanding and monitoring these and other factors, while also analysing empirical evidence found in the enrolment of past studies, will sponsors gain the information necessary to inform the development of effective recruitment management plans (RMPs).

Minding the Gap


Recruitment data from recent dermatology trials can serve as a benchmark for new ones, particularly if they are similarly designed. Applying this information is especially useful when considered in conjunction with the required enrolment rate. A recruitment manager can then look for similar performance metrics points in previous studies with comparable protocols, focusing specifically on both the mandatory and actual enrolment rates. The gap between these is where recruitment management plays a critical role.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Darcee Duke Strube is Senior Vice President of the Dermatology Division at Novella Clinical, responsible for facilitating business alliances around the globe and driving the department’s strategic direction. She has more than 35 years of experience in various clinical operations and business development positions in sponsor, CRO and site organisations. Prior to joining the company, she held key roles in the Clinical Trials Division of TKL Research and earned a BS in Biology from Fairleigh Dickinson University, US.

Milena Reckseit is Director of Recruitment Management for Novella Clinical’s Dermatology Division, where she directs all recruiting and advertising activities for global, multi-centre trials. She utilises her 20 years of patient recruitment experience and strong site relationships to help customers meet their enrolment goals, and her experience includes acne, actinic keratosis, atopic dermatitis, basal cell carcinoma, hyperhidrosis, onychomycosis, psoriasis, rosacea and warts. Milena earned her BS in Marketing and Advertising from Syracuse University, US.
spacer
Darcee Duke Strube
spacer
spacer
spacer
Milena Reckseit
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IONTAS announces a new collaboration to identify novel immunotherapy targets

Cambridge, UK, 07 May 2020: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes. As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.
More info >>

White Papers

Systems Engineering for Complex Portable Medical Device Development

Phillips-Medisize

As the demand for complex, portable medical devices continues to grow, reducing risk and increasing efficiency during the development of these products should be paramount. Taking a systems-engineering (SE) approach to development provides a holistic, organized, and deliberate method for identifying as well as reducing both patient and business risks early in the process. Furthermore, it facilitates efficient progression throughout the entire product development life cycle.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement